Trial Profile
A Single-Dose, Bioequivalence, Pivotal Study of Two Formulations of Dapagliflozin 10 mg Tablets Under Fasting Conditions
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Sep 2021
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Cardiovascular disorders; Chronic heart failure; COVID 2019 infections; Heart failure; Kidney disorders; Myocardial infarction; Obesity; Prediabetic state; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
- Focus Pharmacokinetics; Registrational
- Sponsors Jiangsu Hansoh Pharmaceutical
- 13 May 2021 New trial record